Navigation Links
Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
Date:11/2/2012

NEW BRUNSWICK, N.J., Nov. 2, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, November 10, at approximately 5:00 p.m., Eastern Time, to coincide with the American College of Rheumatology (ACR) Annual Meeting being held in Washington, D.C. 

The presentation will highlight new, pivotal Phase 3 study findings, including;

  • Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial
  • Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-blind, Placebo-controlled Study; Continued Improvement of Signs and Symptoms in Ustekinumab-treated Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-blind, Placebo-controlled Study

The pre-recorded webcast with management from the Company's Janssen pharmaceutical subsidiaries, will provide an update on the Immunology rheumatology pipeline and commercial franchise.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."


'/>"/>
SOURCE Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
2. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
3. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
4. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
5. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
6. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
7. Johnson & Johnson Postpones Medical Devices & Diagnostics Review
8. Johnson & Johnson to Host Medical Devices & Diagnostics Review
9. Johnson & Johnson Announces Plans to Establish Innovation Centers
10. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
11. Johnson Health Tech Statement on Lance Armstrong
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:9/1/2017)... 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is ... experiences — and deliver these experiences as part of Life ... feel and heal better. ... While nothing beats a walk, jog or simply ... Life Environments™ is the next best thing when getting there ...
(Date:8/31/2017)... NEW YORK , Aug. 31, 2017 ... the industry,s must-read guide to the latest innovations happening ... the first industry publication to focus on providing a ... advancements. Ultimately, the issue covers the most innovative companies, ... year. "Everyone in ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... Hair ... new member survey conducted by the International Society of Hair Restoration Surgery ... to 2016 rose 60 percent, with 635,189 procedures performed in 2016. , ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... eat right or exercise more try taking a more holistic approach and use ... Aweganic’s new Amazon essential oil collection is certified USDA guaranteeing that, the new ...
(Date:9/21/2017)... ... 2017 , ... Preora Diagnostics Inc. , a privately ... received two prestigious recognitions that acknowledge the promise of its PWS Nanoctyology platform ... been named a Top 100 Finalist for the 16th annual Chicago Innovation Awards ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand ... to detail to the athletic wear market with the launch of their FlipBelt Crops. ... have their essentials securely at their fingertips while at the gym, on the trail, ...
(Date:9/21/2017)... ... September 21, 2017 , ... In ... and Clark College Emeritus Professor of Education Gregory A. Smith examines student privacy ... Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . ...
Breaking Medicine News(10 mins):